Gliosarcoma is a rare and aggressive subtype of glioblastoma characterized by both glial and sarcomatous components. It accounts for approximately 1.8% to 2.8% of glioblastoma multiforme (GBM) cases and 0.48% of all brain tumors. According to the gliosarcoma pipeline analysis by Expert Market Research, the growing focus on targeted therapies and immunotherapies is driving advancements in gliosarcoma therapeutics. With increasing research funding and clinical trials, the drug pipeline is expected to expand significantly in the coming years. This growth reflects the urgent need for effective gliosarcoma drugs to improve patient outcomes.
Major companies involved in the gliosarcoma pipeline analysis include Epitopoietic Research Corporation, Xynomic Pharmaceuticals, Inc., and others.
Leading drugs currently in the pipeline include ERC1671, M032, C134, and others.
The gliosarcoma drug pipeline is set to expand with increased clinical trials, rising focus on targeted therapies, and growing investment in immunotherapy approaches for aggressive tumor management.
The Gliosarcoma Pipeline Analysis Report by Expert Market Research gives comprehensive insights into gliosarcoma therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for gliosarcoma. The gliosarcoma report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The gliosarcoma pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with gliosarcoma treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to gliosarcoma.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Gliosarcoma is a rare and aggressive form of glioblastoma characterized by both glial and sarcomatous cell components. It typically arises as a primary brain tumor but may also develop following glioblastoma recurrence. The exact cause is unclear, though genetic mutations and treatment-related changes may contribute to its development.
Gliosarcoma treatment involves surgical resection followed by radiotherapy and chemotherapy, commonly with temozolomide. Emerging therapies are under investigation for improved outcomes in recurrent or resistant cases. In April 2024, a Phase 1 clinical trial led by Memorial Sloan Kettering Cancer Center evaluated ABBV-637 or ABBV-155 in combination with ERAS-801 for gliosarcoma and recurrent glioblastoma, focusing on safety and tolerability.
According to Nikolaos Andreas Chrysanthakopoulos et al., 2025, gliosarcoma is a rare and aggressive variant of glioblastoma, accounting for approximately 0.48% of all brain tumors and 1.8% to 2.8% of glioblastoma multiforme cases. It typically affects adults aged 40 to 60, with a higher prevalence in males (male-to-female ratio of 1.8:1). As per Fassil B. Mesfin et al., 2024, gliomas represent the most common primary brain tumors, with an incidence of 6 cases per 100,000 individuals annually in the United States.
This section of the report covers the analysis of gliosarcoma drug candidates based on several segmentations, including:
By Phase
By Drug Class
By Route of Administration
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase I with 56%, covers a major share of the total gliosarcoma clinical trials. It is followed by phase II at 33%, phase III at 6.25%, and early phase I at 4.17%. The strong presence in early-stage clinical development highlights ongoing innovation. This progressive pipeline is expected to enhance treatment options and drive growth in the gliosarcoma treatment landscape.
The drug molecule categories covered under the gliosarcoma pipeline analysis include small molecules, monoclonal antibodies, immunotherapies, and gene therapies. The gliosarcoma report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for gliosarcoma. Immunotherapeutic drug combinations are gaining attention in the gliosarcoma drug pipeline. For example, ERC1671, in combination with Granulocyte-Macrophage Colony-Stimulating Factor and Cyclophosphamide, is under phase II investigation. This regimen, administered with Bevacizumab, aims to enhance immune response against gliosarcoma and glioblastoma cells, offering a novel approach for treating recurrent, bevacizumab-naïve, grade IV malignant gliomas.
The EMR report for the gliosarcoma pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed gliosarcoma therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in gliosarcoma clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for gliosarcoma. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of gliosarcoma drug candidates.
ERC1671, sponsored by Epitopoietic Research Corporation, is currently undergoing a Phase II trial for treating recurrent glioblastoma and gliosarcoma. This immunotherapy combines allogeneic and autologous tumor cell-based vaccines with GM-CSF and oral cyclophosphamide to stimulate immune response. The study is evaluating the efficacy and safety of this regimen with bevacizumab versus placebo. Researchers are aiming to determine improved overall survival in bevacizumab-naïve patients.
M032 and Pembrolizumab are being evaluated in an ongoing Phase I/II trial, sponsored by the University of Alabama at Birmingham. The study is examining the safety, tolerability, and preliminary efficacy of combining Pembrolizumab, an anti-PD-1 monoclonal antibody, with M032, a genetically modified oncolytic herpes simplex virus expressing IL-12. This combination is targeting recurrent or newly diagnosed gliosarcoma, aiming to stimulate and sustain a robust anti-tumor immune response.
C134 is a genetically modified oncolytic herpes simplex virus (HSV-1) designed to infect and destroy gliosarcoma cells without harming healthy brain tissue. Sponsored by the University of Alabama at Birmingham, this Phase I trial is examining the safety, tolerability, and immune-stimulating effects of C134 when administered intratumorally. The virus has been engineered to enhance immune response, aiming to improve therapeutic outcomes in recurrent malignant gliosarcoma.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Gliosarcoma Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for gliosarcoma. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into gliosarcoma collaborations, regulatory environments, and potential growth opportunities.
Upto 35% Off
USD
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share